Table 3 Top CpGs with differential DNAme by SSRI-exposure status.

From: Profiling placental DNA methylation associated with maternal SSRI treatment during pregnancy

Model

CpG

p value

FDR

FDR threshold

Δβ

Chr:position

Gene symbol

Relation to gene

450K locus?

A

cg12900404

9.11e−08

0.06

Moderate confidence

0.11

2: 225811669

DOCK10

1st exon

–

A

cg20877313

6.05e−07

0.20

Low confidence

0.04

12: 56881753

GLS2

1st exon

Yes

B

cg12655501

6.07e−07

0.14

Low confidence

− 0.12

1: 115603524

TSPAN2

Body

–

B

cg26993610

6.26e−07

0.14

Low confidence

0.14

1: 115605466

TSPAN2

Body

–

B

cg14340829

1.80e−07

0.12

Low confidence

− 0.10

8: 923973

–

–

Yes

DMR

cg14921691, cg06762403

–

1.95e−29

–

0.06

12: 56325797–56325867

DGKA

5′UTR, 1st Exon

Yes

  1. Linear modelling p value and false discovery rates (FDR) shown, Δβ is difference in DNAme calculated as Δβ = βSSRI-exposed – βSSRI non-exposed. hg19 chromosome (Chr) and coordinates (Position) for each CpG are indicated, as are genes that each CpG overlaps, and whether each CpG is covered by a probe on the 450K DNA methylation array. A and B in the Model Column refer to model A and model B, DMR refers to the differentially-methylated region analysis.
Back to article page